News | August 13, 2008

Study Says Usage of Ultrasound Contrast Agents in Echocardiography Declined

August 14, 2008 - Arlington Medical Resources (AMR), a provider of market intelligence for the pharmaceutical and diagnostic imaging industries, found the usage of injectable perflutren microsphere ultrasound (micro-bubble) contrast agents, which help to evaluate heart wall motion, declined in the second quarter of 2008 to 22 percent of the usage just two years earlier.

Micro-bubble contrast agents are gas-filled microspheres injected intravenously to improve cardiac ultrasound scanning. In October 2007 the FDA placed a black box warning on ultrasound micro-bubble contrast agents after 10 deaths were reported following administration. Reports of 190 serious but nonfatal reactions were also documented.

“The effects of the black box warnings in 2007 are still being felt in the micro-bubble contrast agent market,” said Anna Fisher, an analyst at AMR. “Even after the FDA revised its warning in May 2008 allowing the agents to be used more broadly, usage still declined in the second quarter of 2008. The role of ultrasound contrast agents continues to be important in the overall echocardiography market because it enhances imaging quality for interpretation. Contrast improves visualization of the left ventricle border, helping the physician evaluate wall motion of the heart.”

The newly released edition of the U.S. Echocardiography Monthly Monitor also finds that the total number of patients undergoing echocardiographies in the U.S. had declined by 17,095 in June 2008. The total number of patients undergoing contrast enhanced echocardiography for the U.S. market also declined slightly by 2,137.

For more information: www.AMR-data.com

Related Content

360 Photos | Magnetic Resonance Imaging (MRI) | May 17, 2019
This is a dedicated cardiac Siemens 1.5T MRI system installed at the Baylor Scott White Heart Hospital in Dallas.
360 Photos | Angiography | May 17, 2019
This is a view inside one of the 11 cath labs at ...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Clarius Releases Clarius Live Ultrasound Telemedicine Solution
Technology | Ultrasound Imaging | May 15, 2019
Clarius Mobile Health released a telemedicine solution called Clarius Live. The simple-to-use feature allows any...
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
Hong Kong Polytechnic University Develops Palm-sized 3-D Scoliosis Ultrasound Imaging System
News | Ultrasound Imaging | May 03, 2019
The Hong Kong Polytechnic University (PolyU) announced the development of a palm-sized 3-D ultrasound imaging system...
New Guideline Published for Evaluation of Valvular Regurgitation After Catheter-based Valve Interventions
News | Cardiovascular Ultrasound | April 30, 2019
A new document compiled by four cardiac imaging professional societies provides a resource to guide clinicians in best...
Six Predictions on How the Ultrasound Systems Market Will Expand Through 2022
News | Ultrasound Imaging | April 26, 2019
With healthcare costs continuing to rise, affordable and accurate imaging and diagnosis achieved through ultrasound...